Clinical Research Papers:
Survival benefit of radiotherapy on patients with earlystage extranodal nasaltype natural killer/Tcell lymphoma: an analysis of the surveillance epidemiology and end results database
Metrics: PDF 530 views | Full Text 751 views
Shi-Long Zhang1, Zhi-Ming Wang2, Yi-Feng Sun1 and Jian-Min Xu1
1Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
2Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
Correspondence to:
Jian-Min Xu, email: [email protected]
Keywords: extranodal natural killer/T-cell lymphoma; radiotherapy; surveillance epidemiology and end results; prognostic factors
Received: July 31, 2017 Accepted: November 13, 2017 Published: January 03, 2018
ABSTRACT
Background: Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare malignant lymphoid malignancy. The survival benefit of radiotherapy (RT) in early-stage ENKTL patients remains controversial. This study was conducted to investigate the prognostic factors, and evaluate survival benefit of RT in early-stage ENKTL patients.
Materials and Methods: Early-stage ENKTL patients between 2004 and 2013 were searched from the Surveillance Epidemiology and End Results (SEER) database. Clinical characteristics including sex, age at diagnosis, race, marital status, era of diagnosis, histology, Ann Arbor stage and RT were summarized. Kaplan–Meier and multivariate Cox proportional hazards regression analysis were performed to investigate the independent prognostic factors for early-stage ENKTL patients. Subgroup analysis was conducted to evaluate the benefit of RT on overall survival (OS) and cancer specific survival (CSS) based on different Ann Arbor stages.
Results: Patients with early-stage ENKTL were more likely to be younger, present with B symptoms. RT was more likely used for younger patients and those presented with B symptoms. Kaplan–Meier and multivariate Cox regression analysis showed that Ann Arbors stage and RT were the independent prognostic factors for survival (p < 0.05). And RT was associated with a lower risk of mortality for OS and CSS. Subgroup analysis based on different Ann Arbor stages showed that RT can decrease 66% risks of mortality in Stage I and more than 60% risks of mortality in Stage II (p < 0.005).
Conclusions: RT could contribute to significant survival benefit among early-stage ENKTL patients. Significant survival benefit of RT still remained in any disease stage.